Mizuho Reiterates Outperform Rating on Insmed (INSM), Boosts PT to $110
A scientist using sophisticated laboratory equipment to analyze a sample of a therapeutic candidate. The analyst believes the trial's success strengthens Insmed's growth outlook and opens the door for further upside to current earnings estimates. The tone of the note reflects the analyst's strong confidence in TPIP's potential and its impact on Insmed's long-term value. Insmed Inc. (NASDAQ:INSM) is a global biopharmaceutical company that develops therapies for serious diseases. It has a commercial product, ARIKAYCE, and a pipeline that includes clinical-stage programs, brensocatib, TPIP, and INS1201, as well as pre-clinical research programs. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Tilray Eyes Reverse Stock Split As Nasdaq Listing Compliance Pressure Mounts
Tilray Brands, Inc. (NASDAQ:TLRY) shares slipped Thursday after the company said it is seeking more time from Nasdaq to restore compliance with the exchange's continued listing rules tied to its per-share price. The cannabis and consumer packaged goods firm also signaled it may pursue a shareholder-approved reverse stock split if needed to keep its listing intact. Tilray has filed a request to extend the window to regain eligibility under Nasdaq standards and is evaluating several capital-structure options, including a potential reverse split, to ensure move aims to protect its listing while the board reviews next steps. Chief Executive Irwin Simon said that recent trading strength has followed President Trump's review of cannabis rescheduling and reflects confidence in Tilray's diversified platform. Tilray's trading levels have appreciated in recent weeks following President Trump's review of cannabis rescheduling. Tilray also highlighted momentum in its medical business in Europe. Its medical unit's wholly owned subsidiary FL Group S.R.L. formed a new distribution alliance in Italy with L. Molteni & C. dei Alitti Società di Esercizio S.p.A. to broaden access to cannabis extracts for patients, reflecting growing demand and new partnership opportunities across the region. The extension request underscores Tilray's effort to maintain its Nasdaq listing while navigating market volatility and evolving U.S. policy signals around cannabis. A reverse split remains one option to rectify minimum bid price thresholds, as the company balances capital-market requirements with expansion in medical and wellness categories. Price Action: TLRY shares are trading lower by 6.12% to $1.170 at last check Thursday. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? TILRAY BRANDS (TLRY): Free Stock Analysis Report This article Tilray Eyes Reverse Stock Split As Nasdaq Listing Compliance Pressure Mounts originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
JD.com's Investments Pay Off With Massive Jump In New Business Revenue
China-based (NASDAQ: JD) reported fiscal second-quarter results on Thursday. The company reported a quarterly revenue growth of 22.4% year-over-year (Y/Y) to $49.8 billion, beating the analyst consensus estimate of $46.9 billion. JD posted an adjusted net income per ADS of 69 cents, beating the analyst consensus estimate of 44 net product revenue increased by 20.7% Y/Y at $39.42 billion. Net service revenues rose 29.1% Y/Y to $10.36 billion. JD Retail revenue climbed 20.6% Y/Y to $43.3 billion, Logistics revenue gained 16.6% Y/Y to $7.2 billion, and the new business revenues grew 198.8% Y/Y to $1.9 billion. marketing expenses rose 127.6% to $3.8 billion in the quarter, forming 7.6% of revenues, up by 350 bps. Operating margin loss was (0.2)% for the quarter, compared to 3.6% Y/Y. Adjusted operating margin stood at 0.3% compared to 4.0% Y/Y, primarily attributable to increased strategic investment in new business initiatives. View more earnings on JD JD Retail's operating margin rose 60 bps to 4.5%. Adjusted EBITDA decreased 77.8% Y/Y to $419 million, with a 0.8% margin, compared to 4.6% Y/Y. generated $3.07 billion in free cash flow for the quarter and $3.41 billion in operating cash flow. The company held $31.2 billion in cash and equivalents as of June 30, 2025. CEO Sandy Xu attributed its second-quarter growth to strong momentum in its core JD Retail business and New Businesses, particularly JD Food Delivery. Xu pointed to gains in user traffic, active customers, and shopping frequency, noting that JD Food Delivery advanced in order volume, merchant base, and rider recruitment, supported by synergies with JD's broader retail ecosystem. She said the company will keep its core retail segment as a foundation while investing in strategic growth areas to enhance user experience, cut costs, and improve efficiency. stock declined over 6% year-to-date as investors remain wary of its food delivery business profitability. Price Action: JD stock is trading higher by 0.34% to $32.62 at last check Thursday. Photo by Freer via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? (JD): Free Stock Analysis Report This article Investments Pay Off With Massive Jump In New Business Revenue originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why AI Robotics Stock Symbotic Surged 38.9% in July
Key Points More analysts are turning bullish on Symbotic after its Walmart deal. The stock has more than doubled in just six months. Symbotic shares could cool off a bit from here, but there's nothing to worry about. 10 stocks we like better than Symbotic › Symbotic (NASDAQ: SYM) stock has gone ballistic. A stunning rally of 38.9% in July drove the stock's half-yearly performance to a staggering 127.5%, according to data provided by S&P Global Market Intelligence. On Aug. 5, Symbotic hit a 52-week high of $64.16 per share. Symbotic automates warehouses and distribution centers with its artificial intelligence (AI)-powered robots and software. Symbotic's deal with Walmart (NYSE: WMT), in particular, has spurred massive investor interest in its stock, with several analysts upgrading their price targets in recent weeks. Why are analysts turning bullish on Symbotic stock? Analysts from Citi, Arete, Northland, and Oppenheimer were among those that initiated coverage or upgraded their price targets on Symbotic stock in July. While Arete has a price target of $50 per share on Symbotic, analysts from Northland raised their price target on the AI stock to $56 per share from $35 a share. Citi analyst Andrew Kaplowitz upped the stock's price target to $60 from $29 per share. Oppenheimer analyst Colin Rusch, meanwhile, raised Symbotic's price target from $35 per share to $54 a share in July, and then by another $5 in early August. In January, Symbotic acquired Walmart's advanced systems and robotics (ASR) business and signed a commercial agreement with the retail giant to deploy robotics automation systems for up to 400 accelerated pickup and delivery (APD) centers at Walmart stores over the next few years. Symbotic estimates incremental backlog of $5 billion from the deal. As news of Walmart testing "dark stores" to fulfill online orders hit the headlines in late June and through July, investors analysts bumped up their expectations from Symbotic stock and drove its price higher. Shares hit a new 52-week high of $64.16 ahead of earnings on Aug. 5. Could Symbotic stock lose momentum from here? Symbotic beat estimates with 26% year-over-year growth in revenue for its third quarter. Its net loss, however, widened to $32 million from $21 million a year ago because of restructuring charges. Moreover, the company's Q4 revenue guidance of $590 million to $610 million would mean only 4% year-over-year growth at the midpoint. Investors don't want to see a deceleration in sales from a growth stock that's yet to turn profitable. Yet investors should also look beyond the headlines. Symbotic is ready to deploy a next-generation storage system at warehouses that should significantly improve storage capacity and handling. The company, however, is facing startup problems, but expects them to be a temporary blip. Management insisted that none of it affects the company's backlog, which stands at a solid $22.4 billion today. To put that number into perspective, Symbotic generated revenue worth $1.8 billion last year. Long story short, Symbotic could face some quarters of slow revenue growth, but that shouldn't hurt the long-term growth potential of this AI and robotics stock. Should you invest $1,000 in Symbotic right now? Before you buy stock in Symbotic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Symbotic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Citigroup is an advertising partner of Motley Fool Money. Neha Chamaria has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Symbotic and Walmart. The Motley Fool has a disclosure policy. Why AI Robotics Stock Symbotic Surged 38.9% in July was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
